Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
5.1 As a condition of the positive recommendation and the managed access agreement, the company is required to collect efficacy data from the SOLO‑1 trial.